# Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)

> **NCT00116376** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** AEE788

## Key facts

- **NCT ID:** NCT00116376
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2015-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116376, "Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00116376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*